Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in ...

The late-stage chronic kidney disease (CKD) market is experiencing significant growth, driven by rising global prevalence of diabetes, hypertension, and aging populations. Advanced treatments like ...

The clinic and executive compensation measures appear to be the next chapter of the same strategy to expand the union’s power ...

The Dialysafe trial aimed to reduce episodes of intradialytic hypotension during hemodialysis sessions at the clinic level.

Why funding lags: Kidney disease research receives far less funding than other chronic conditions, limiting innovation and keeping dialysis as the default treatment. Who’s driving change: Companies ...

May 5 (Reuters) - Fresenius Medical Care said on Tuesday its revenue fell 6% in the first quarter of 2026, weighed down by significant currency effects, mainly from the weak U.S. dollar, and recent ...

The number of foreign-owned business rose 4% last year in California despite the Trump administration's trade wars, with ...

UB faculty member Calvin Meaney highlights the benefits of relying on pharmacists, especially with the shortage of ...

The California Department of Managed Health Care and the Department of Public Health defended the law in court, represented ...

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Fresenius Medical Care FME3.82%increase; green up pointing triangle shares fell after the German dialysis specialist forecast flattish revenue and adjusted earnings in the year ahead amid regulatory ...

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.